Vnitr Lek 2021, 67(6):330-333 | DOI: 10.36290/vnl.2021.088

Nintedanib in the treatment of systemic rheumatic disease-associated interstitial lung disease

Ondřej Zela

Plicní oddělení Nemocnice ve Frýdku-Místku, p. o.

Systemic rheumatoid diseases form a large group of entities with variable clinical picture and different involvement and degree of organ impairment. Respiratory tract represents major site of damage, with lung interstitium, pleura, pulmonary vasculature and airways possibly affected. In systemic sclerodermia and rheumatoid arthritis, lung disease is the most significant cause of morbidity and mortality. Breathing difficulties may either present as first symptoms of underlying rheumatoid disease or may appear at any time during the course of the disease. Rheumatologists should routinely screen their patients for possible lung impairment. Similarly, extrapulmonal signs should be assessed by pulmonologists in patients referred for dyspnea. Currently, novel antifibrotic therapy is available not only for patients with idiopathic pulmonary fibrosis (IPF), but also for selected group of patients with non-IPF progressive fenotype associated interstitial lung disease having solid evidence-based background. Interdisciplinary approach in terms of collaboration between pulmonologist and rheumatologist is of key importance as proper identification of possible candidates and early onset of therapy is crucial.

Keywords: systemic rheumatic diseases, interstitial lung disease, nintedanib, INBUILD, INPULSIS.

Published: October 13, 2021  Show citation